List of Excipients in Branded Drug CYTOTEC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	CYTOTEC	misoprostol	0025-1451	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	CYTOTEC	misoprostol	0025-1451	HYDROGENATED CASTOR OIL
Pfizer Laboratories Div Pfizer Inc	CYTOTEC	misoprostol	0025-1451	HYPROMELLOSE
Physicians Total Care Inc	CYTOTEC	misoprostol	54868-2176	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	CYTOTEC	misoprostol	54868-2176	HYDROGENATED CASTOR OIL

Cytotec Excipient Strategy, Patent Position, and Commercial Opportunities for Misoprostol

Last updated: August 9, 2026

Cytotec is Pfizer’s branded misoprostol tablet, approved in the United States to reduce the risk of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Its active-ingredient, formulation, and primary regulatory exclusivities are long expired. Current value lies in generic supply, differentiated dosage forms, institutional distribution, global access, and formulation improvements rather than in the original Cytotec patent estate.

What is Cytotec and how is misoprostol formulated?

Cytotec contains misoprostol, a synthetic prostaglandin E1 analog. U.S. labeling identifies 100 microgram and 200 microgram tablets. The labeled inactive ingredients are hydrogenated castor oil, microcrystalline cellulose, sodium starch glycolate, and hypromellose.[1]

Product attribute	Cytotec position
Active ingredient	Misoprostol
Therapeutic class	Prostaglandin analog
U.S. dosage forms	100 mcg and 200 mcg tablets
U.S. labeled indication	Reduction of NSAID-induced gastric ulcers
Manufacturer of branded product	Pfizer
Administration	Oral tablet
Biosimilar pathway	Not applicable
Primary generic pathway	ANDA under Hatch-Waxman
Key formulation issue	Low-dose content uniformity and stability
Current exclusivity	Original patent and regulatory exclusivity periods have expired

The excipient system is conventional but commercially important. Hydrogenated castor oil can support tablet structure and lubrication. Microcrystalline cellulose provides compactability. Sodium starch glycolate promotes disintegration. Hypromellose can function as a binder and film-forming excipient.

Because the active dose is only 100 or 200 micrograms, manufacturing controls are more important than the absolute excipient cost. Small errors in blending, segregation, or tablet weight can produce material potency variation. A generic developer must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements, even though the formulation uses inexpensive, widely available excipients.[2]

What excipients protect Cytotec and its generic formulations?

No current commercial opportunity appears to depend on a live, enforceable Cytotec excipient patent in the United States. The labeled excipients are established pharmaceutical materials, and the original product was approved decades ago. A developer could still seek patent protection for a new formulation, but the protection would need to arise from a novel and non-obvious combination, manufacturing method, stability profile, or delivery system.

Excipient functions in the Cytotec tablet

Excipient	Likely technical role	Commercial relevance
Hydrogenated castor oil	Lubrication, tablet integrity, hydrophobic structural aid	May influence dissolution and compression behavior
Microcrystalline cellulose	Diluent and dry-binder	Supports direct compression and dose uniformity
Sodium starch glycolate	Superdisintegrant	Helps achieve rapid tablet breakup
Hypromellose	Binder and film-former	Supports granulation, coating, and mechanical strength

A generic formulation does not need to copy the branded excipient composition. An ANDA applicant generally may use a different inactive-ingredient system if the product satisfies pharmaceutical equivalence, bioequivalence, quality, labeling, and safety requirements.[2]

Potential alternative excipients include lactose, mannitol, dibasic calcium phosphate, crospovidone, croscarmellose sodium, povidone, low-substituted hydroxypropyl cellulose, and alternative lubricants. Each alternative creates tradeoffs involving blend uniformity, tablet hardness, disintegration, dissolution, moisture exposure, and supplier qualification.

What formulation patents could protect a new misoprostol product?

A new misoprostol formulation could pursue several patent claim categories:

1. A defined excipient ratio that improves content uniformity.
2. A low-moisture composition that improves chemical stability.
3. A coated tablet that limits degradation during storage.
4. A rapidly disintegrating oral tablet.
5. A sublingual, buccal, vaginal, or rectal dosage form.
6. A unit-dose package that limits exposure to heat, humidity, or oxygen.
7. A manufacturing process that reduces content variability.
8. A combination product containing misoprostol and another active ingredient.
9. A dosage regimen tied to a specific indication or patient population.

The strongest patent opportunity is unlikely to be a bare list of familiar excipients. Such claims face substantial obviousness risk because standard tablet diluents, binders, disintegrants, and lubricants are well known. More defensible claims would connect the formulation to a measurable technical result, such as improved stability under defined humidity conditions, a narrow dissolution profile, or a manufacturing process that solves low-dose blend segregation.

Which formulation concepts have the highest commercial value?

A standard immediate-release tablet has the lowest development risk and the greatest generic-market fit. A dispersible or rapidly disintegrating tablet could improve administration in settings where swallowing is difficult, but it would require a new pharmaceutical-development package and may create additional labeling or stability obligations.

A vaginal or sublingual product could target obstetric and reproductive-health use, but the regulatory and commercial pathway would differ from the approved Cytotec ulcer indication. A new route of administration could require a 505(b)(2) application rather than a conventional ANDA if the product cannot demonstrate equivalence to the reference listed drug.

When does Cytotec lose exclusivity?

Cytotec’s original U.S. exclusivity has expired. The product was approved in 1988, and its primary composition and product-protection periods are historical rather than current.[1,3]

Exclusivity category	Cytotec status
Original compound patent	Expired
Original product/formulation patents	Expired or no longer commercially determinative
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current relevance
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Current market exclusivity	No identified active exclusivity blocking ordinary generic entry

The practical consequence is that generic competition can proceed without waiting for an original Cytotec patent term. Any current barrier would more likely arise from manufacturing capability, regulatory quality requirements, supply constraints, commercial contracting, or patents on a later-developed product rather than from the original Cytotec tablet.

What is the Orange Book status of Cytotec?

The FDA Orange Book is the controlling source for current listed patents, reference listed drug status, therapeutic equivalence codes, and product information.[3] Cytotec is associated with the misoprostol reference product and NDA 019268 in FDA drug databases.[1]

For an ANDA applicant, the relevant questions are whether:

• Cytotec remains the reference listed drug for the proposed strength and dosage form;
• any patents are currently listed against the reference product;
• a Paragraph IV certification is required;
• the applicant must provide a section viii statement for a method-of-use patent; and
• the proposed labeling can omit unapproved uses under the statutory carve-out process.

Given the age of Cytotec, an ordinary generic applicant would generally expect an expired-patent or no-current-patent pathway rather than a commercially significant Paragraph IV campaign. The Orange Book should be checked at filing because listings and delistings can change.

Are Paragraph IV challenges relevant to misoprostol?

Paragraph IV litigation is unlikely to be the principal barrier for a standard generic Cytotec-equivalent tablet. A Paragraph IV certification is relevant only if the Orange Book lists an unexpired patent that the applicant asserts is invalid, unenforceable, or not infringed.[2]

The more significant legal issues may involve:

• product-specific patents on newer formulations;
• method-of-use patents covering reproductive-health or obstetric applications;
• patents owned by third parties rather than Pfizer;
• patent challenges to combination products;
• state or institutional restrictions affecting distribution.

A generic applicant also must consider whether it can use a section viii statement to omit a patented method of use from its labeling. This analysis is especially important for misoprostol because clinical use extends well beyond the original ulcer indication, while the FDA label remains narrower than many real-world uses.

What FDA regulatory status applies to Cytotec and misoprostol generics?

Cytotec is an approved prescription drug. Misoprostol generics can generally pursue ANDA approval when they match the reference listed drug in active ingredient, strength, dosage form, route, and labeling, subject to FDA requirements.[1,2]

The labeled Cytotec warning is significant. Misoprostol can cause uterine contractions, abortion, premature birth, or birth defects. The U.S. label includes a boxed warning concerning pregnancy and requires careful prescribing and dispensing controls.[1]

Misoprostol has important clinical uses outside the Cytotec label, including cervical ripening, labor induction, management of postpartum hemorrhage, and medication abortion in combination with mifepristone. Those uses do not automatically become FDA-approved indications for the misoprostol tablet. A company seeking to commercialize a product around those uses may need a new application, a 505(b)(2) strategy, or a combination-product analysis.

Misoprostol is a small-molecule drug. Biosimilar risk does not apply. Competitive risk comes from generic tablets, compounded products in certain settings, alternative prostaglandins, mifepristone-containing regimens, and different dosage forms.

What commercial opportunities exist for Cytotec excipient innovation?

The strongest opportunities fall into five categories.

1. Low-cost, high-volume generic tablets

The standard 100 microgram and 200 microgram immediate-release tablets offer the clearest route to market. Manufacturing economics depend on:

• low-dose blend uniformity;
• robust tablet compression;
• stable supply of pharmaceutical-grade excipients;
• control of moisture and temperature;
• efficient packaging;
• reliable dissolution performance.

The market is likely price-sensitive. A formulation that uses widely available excipients and avoids complex processing is more commercially attractive than a premium excipient system without a clear clinical or shelf-life benefit.

2. Heat- and humidity-stable products

Misoprostol supply is particularly relevant in low-resource and emergency-care settings. A formulation or package that maintains potency under elevated temperature and humidity could support procurement contracts, global-health programs, and institutional tenders.

The patentable contribution may reside in the combination of tablet composition and packaging rather than in the tablet alone. Aluminum-aluminum blister systems, high-barrier films, desiccant-assisted packaging, and individually sealed unit doses could reduce degradation risk. Packaging claims require careful drafting because the commercial advantage may be difficult to defend if competitors can achieve the same result with different materials.

3. Unit-dose institutional products

Hospitals, clinics, emergency departments, and public-health programs may value unit-dose packaging, barcoding, tamper evidence, and simplified dispensing. A unit-dose product can also reduce medication errors involving the 100 microgram and 200 microgram strengths.

This opportunity is operational rather than purely pharmaceutical. The value proposition must combine reliable supply, packaging compliance, predictable shelf life, and procurement efficiency.

4. Alternative dosage forms

Sublingual, buccal, vaginal, rectal, orally disintegrating, and dispersible products could address administration constraints. These products may be commercially differentiated, but they carry higher regulatory risk because they may not qualify as simple ANDA copies of Cytotec.

A new route or dosage form can create patent opportunities around release rate, mucoadhesion, dose uniformity, excipient compatibility, and packaging. It also creates additional clinical and regulatory work.

5. Combination products

Misoprostol has commercial relevance in combination with NSAIDs, particularly where gastroprotection is part of the treatment strategy. A fixed-dose NSAID-misoprostol product can improve adherence but raises formulation, stability, dosing, and regulatory complexity.

Combination-product patents may cover the ratio of actives, release profiles, tablet architecture, or indication. These products compete with separate prescriptions and generic coadministration, which can weaken pricing power.

What patent litigation and settlement risks affect Cytotec?

No major current litigation risk can be identified from the historical Cytotec product position alone. The principal litigation risks for a new entrant would arise from later patents covering:

• a specific excipient matrix;
• a moisture-protective package;
• a new route of administration;
• a fixed-dose combination;
• a manufacturing process;
• a reproductive-health method of use.

A Paragraph IV notice could trigger litigation and a potential 30-month stay if a qualifying listed patent were involved.[2] For a conventional Cytotec-equivalent tablet with expired original protection, that scenario is less likely than ordinary generic entry.

Settlement agreements could still affect market timing if a later patent owner litigates a differentiated product. Any such agreement would require review for launch restrictions, authorized-generic rights, supply obligations, and antitrust exposure. No current commercially material Cytotec settlement should be assumed without a live court docket or FTC filing.

How strong is the Cytotec patent estate?

The original Cytotec estate is commercially weak because the product is old, the active ingredient is well established, and the primary patent terms have ended. A new entrant faces greater risk from product quality and regulatory execution than from the historical Pfizer estate.

Patent category	Current strategic strength
Original misoprostol compound claims	Low; expired
Original Cytotec tablet claims	Low; expired or non-blocking
Familiar excipient combinations	Low to moderate; obviousness risk
Novel stability formulation	Moderate if supported by data
Packaging and environmental protection	Moderate, with design-around risk
New route of administration	Moderate to high if clinically differentiated
Combination product	Moderate to high, depending on claim scope
Method-of-use patents	Variable; depends on listing, validity, and labeling

Geographic coverage also matters. U.S. protection is largely historical, while other jurisdictions may have different patent records, regulatory requirements, and procurement dynamics. A global launch requires country-by-country review of patent registers, data exclusivity, local product registration, and import controls.

What generic launch scenarios exist for misoprostol?

Scenario 1: Standard ANDA launch

A company launches 100 microgram and 200 microgram immediate-release tablets using a conventional excipient system. This is the lowest-risk strategy and is most likely to face price competition.

Scenario 2: Differentiated stability product

A company launches the same strengths with improved packaging or stability data. The product may command institutional value if it demonstrates longer shelf life or better performance in hot and humid environments.

Scenario 3: 505(b)(2) alternative dosage form

A company develops a sublingual, buccal, vaginal, rectal, or dispersible formulation. The opportunity is differentiated, but development costs and clinical requirements are higher.

Scenario 4: Combination product

A company develops an NSAID-misoprostol product or another fixed-dose combination. The commercial case depends on adherence, reimbursement, physician adoption, and competition from separate generic tablets.

Scenario 5: Global-access product

A manufacturer focuses on WHO-aligned procurement, low-cost packaging, and robust distribution for maternal-health and reproductive-health programs. Regulatory and political conditions vary sharply by country.

Key Takeaways

• Cytotec is an old misoprostol tablet product with expired primary patent and regulatory exclusivities.
• The labeled excipients are hydrogenated castor oil, microcrystalline cellulose, sodium starch glycolate, and hypromellose.
• Standard generic tablets offer the clearest commercial opportunity but are likely to face strong price competition.
• The best formulation opportunities involve low-dose content uniformity, heat and humidity stability, unit-dose packaging, and alternative delivery routes.
• Misoprostol is a small molecule, so biosimilar competition is irrelevant.
• Paragraph IV risk is limited for the historical Cytotec product but may arise for later patents covering new formulations, combinations, manufacturing processes, or uses.
• Reproductive-health and obstetric uses create commercial demand but are not all included in the FDA Cytotec label.
• A new route or combination product may require a 505(b)(2) application rather than a conventional ANDA.
• Product-specific revenue for branded Cytotec is not publicly disclosed as a separate business line; current value is concentrated in generic and institutional markets.

FAQs

Can a generic company copy Cytotec’s excipients?

Yes. A generic company can use the same inactive ingredients or a different formulation if it satisfies FDA pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements.

Is misoprostol protected by a current U.S. composition patent?

The original misoprostol composition protection is historical and expired. Current protection would need to arise from a later formulation, process, package, combination, or method-of-use patent.

Is Cytotec used for medication abortion?

Misoprostol is used in medication-abortion regimens, often with mifepristone, but those uses are distinct from Cytotec’s FDA-approved ulcer indication and labeling.

What packaging is most relevant for misoprostol stability?

High-barrier unit-dose packaging, including aluminum-based blister systems, is commercially relevant where protection from humidity, heat, and oxygen is required.

Can a new misoprostol vaginal product use the ANDA pathway?

Not necessarily. A product with a different route, dosage form, or clinically meaningful formulation difference may require a 505(b)(2) application or another regulatory pathway rather than a simple ANDA.

References

1. U.S. Food and Drug Administration. (2023). Cytotec (misoprostol) tablets prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.